Referee #1 (Remarks to the Author):
In this paper, Dormann and colleagues have characterized a non classical nuclear localization signal (NLS) sequence in the FUS/TLS protein and have examined the potential relationship between mutations in this region and familial case of amyotrophic lateral sclerosis. On the base of sequence homology with other similar NLS signals they have validated the hypothesis that the import of FUS in the nucleus is directly dependent on its interaction with with transportin 1 (Trp1). Moreover, they demonstrate that cellular stress can induce FUS clustering within stress granules in cells, suggesting that both nuclear import defects and cellular stress, are involved in the pathogenesis of FUSassociated diseases.
In general, this is a straightforward, insightful, and clearly written report. The identification and characterization of this novel NLS signal in the C-terminal end of FUS is very well done and validated. Moreover, the suggestion that mutations in this novel NLS signal might be directly connected with age of onset of ALS (depending on their degree of nuclear export impairment) is a potentially very important and exciting finding.
There are just a few issues that should be clarified by the authors.
First of all, the authors have performed an extensive set of convincing assays looking at the effects of FUS mutations on its cytosolic/nuclear distribution. Do they also have some evidence that, beside the correlation with the age of disease onset, expression of these mutants is toxic to the cells (ie. have they measured LDH release following transfection at least for the highly mislocalized P525L mutant, etc.)?.
Secondly, several reports have recently shown that TDP-43 can also localize in stress granules (Colombrita et al., 2009 , Volkening et al., 2009 , and Freibaum et al., 2010 . Have the authors checked for the presence of TDP-43 in the FUS-containing stress granules they observe under their experimental conditions?. In the discussion, the authors correctly make the parallelism between the presence of FUS (and absence of TDP-43) in the stress granules observed in basophilic inclusion body disease (BIBD) and neuronal intermediate filament inclusion disease (NIFID). Therefore, it would be very important to check whether the stress granules observed by the authors in the different conditions they have assayed (ie. GFP-M9M treatment, heat shock, ans especially in the presence of FUS mutations etc.) only contain FUS and not TDP-43. In fact, if TDP-43 was recruited to the stress granules induced by the authors, then the hypotheses they make between FUS recruitment to stress granules and pathogenesis might have to be somewhat revised, at least at the discussion level.
Finally, considering the strong labelling for PABP-1 in FUS-pathology and in the FUS-containing stress granules observed by the authors, have they tried to perform co-IP analyses to check for an eventual direct interaction between these two proteins?.
Referee #2 (Remarks to the Author):
Overview: Patients carrying point mutations in the C-terminus of FUS show neuronal cytoplasmic FUS-positive inclusions, whereas in healthy controls FUS is predominantly nuclear. The group demonstrate that a non-classical PY nuclear localization signal (NLS) in the C-terminus of FUS is necessary for nuclear import. The majority of fALS-associated mutations occur within the NLS and impair nuclear import to a degree that correlates with the age of disease onset. Nuclear import of FUS appears to be dependent on Transportin, and interference with this transport pathway leads to cytoplasmic redistribution and recruitment of FUS into stress granules. A two pathological hits is proposed, namely nuclear import defects and cellular stress; both would be involved in the pathogenesis of FUS-opathies.
Minor comments:
1. The mutations that the authors focused on to determine their subcellular localization. It is rather surprising that they overlooked the two most frequent mutations, which have been identified by a number of groups, R521C and R521H. The authors did however analyze the pattern of expression in post-mortem tissue of an ALS patient with the R521C.
2.The pathological data do not bring much novelty to this article. Also, the authors should be cautious not to overinterpret their results in the discussion section since very few cases with FUS mutations have been identified up to now to discuss the severity of disease in these ALS patients.
3.There are at least five studies on localization of TDP-43 in stress granules. The authors should certainly review this literature and offer an hypothesis as to why in their experiments FUS was present whereas TDP-43 was not.
Referee #3 (Remarks to the Author): Dormann et al show that ALS-associated FUS mutations are concentrated in a transportin-dependent nuclear localization domain. Deletion of this domain or introduction of disease-associated point mutations re-directs FUS to the cytoplasm of HeLa cells as well as hippocampal and cortical neurons. Moreover, knockdown of transportin or expression of a transportin inhibitor peptide (M9M), re-directs wild type FUS to the cytoplasm of HeLa cells and neuronal cells. In M9M-expressing cells, cytoplasmic FUS is concentrated at TIAR+/PABP-1+ stress granules. Mutant, but not wild type, FUS is also concentrated at stress granules in HeLa cells and hippocampal neurons exposed to heat shock. Finally, immunohistochemical staining of motor neurons in ALS as well as hippocampal cells in FTLD-U, reveal PABP-1+ inclusions that may be stress granules. These remarkable findings link mutations in FUS to the assembly of stress granules and suggest that an altered stress response program plays a pathogenic role in the FUS-opathies. The experiments are carefully done, exceptionally well controlled, and technically sound. For the most part the conclusions are justified by the data. The authors should address the following points:
1. The observed FUS+/TIAR+/PABP-1+ granules are likely to be stress granules. However, a function verification would strengthen this claim. The authors should verify that cycloheximide dissolved these granules in the cultured cells shown in Figure 5 .
2. The demonstration that PABP-1+ granules are found in tissue sections from patients with ALS and FTLD-U is suggestive of stress granules, but additional evidence would be welcome. Is it possible to subject these tissues to in situ hybridization using oligo-dT to determine whether poly(A)+ RNA is present at these granules?
3. The quantification of nuclear and cytoplasmic localization is expressed as a mean +/-SEM. Is this from a single experiment or the average from several independent experiments? 1st Revision -authors' response 28 May 2010
Reviewer 1:
The reviewer finds that this is a "straightforward, insightful, and clearly written report" and that "the identification and characterization of this novel NLS signal in the C-terminal end of FUS is very well done and validated". He/she states that the observed correlation between mutations in the NLS and the age of disease onset "is a potentially very important and exciting finding".
Specific points:
( As suggested by the reviewer, we have addressed a potential toxicity of the strongly mislocalized FUS-P525L mutant in primary neurons. To do so, we performed TUNEL staining on rat hippocampal neurons transfected with empty vector, FUS-WT or FUS-P525L 2 or 4 days prior to staining. As shown in supporting figure R1 , no difference between vector-transfected, FUS-WT-or FUS-P525L-transfected cells could be observed, suggesting that cytosolically mislocalized FUS does not induce apoptosis within a few days, at least in neuronal cultures in vitro. Thus, toxicity may be caused by a different mechanism, such as loss of FUS from the nucleus. Alternatively, toxicity might only be observed upon prolonged presence of FUS in the cytosol and after additional stress, as suggested in the discussion and the new Fig. 9. (2) Secondly, several reports have recently shown that TDP-43 can also localize in stress granules (Colombrita et al., 2009 , Volkening et al., 2009 , and Freibaum et al., 2010 
. Have the authors checked for the presence of TDP-43 in the FUS-containing stress granules they observe under their experimental conditions? In the discussion, the authors correctly make the parallelism between the presence of FUS (and absence of TDP-43) in the stress granules observed in basophilic inclusion body disease (BIBD) and neuronal intermediate filament inclusion disease (NIFID). Therefore, it would be very important to check whether the stress granules observed by the authors in the different conditions they have assayed (ie. GFP-M9M treatment, heat shock, and especially in the presence of FUS mutations etc.) only contain FUS and not TDP-43. In fact, if TDP-43 was recruited to the stress granules induced by the authors, then the hypotheses they make between FUS recruitment to stress granules and pathogenesis might have to be somewhat revised, at least at the discussion level.
We agree with the reviewer that it is an important and interesting point to check whether FUS-containing stress granules contain TDP-43 or not. In supplementary figure S2 of the original manuscript, we had already shown that upon GFP-M9M expression, FUS but not TDP-43 redistributes to cytoplasmic granules (Fig. S2B) . To make this point more clear, we now moved this supplementary figure into the main section of the revised manuscript (new Fig. 5D ). In addition, we followed the reviewer's advice and analyzed the localization of TDP-43 after heat shock in the presence of the FUS-P525L mutation. As shown in new Fig. 8C , TDP-43 remains nuclear upon heat stress and is not recruited into FUS-P525L-containing stress granules. This is in agreement with the GFP-M9M experiment (Fig. 5D ) and our observation that TDP-43 is absent from FUS inclusions in fALS or FTLD-FUS patients (Fig. 7) .
Since indeed several other reports have described TDP-43 in stress granules (Moisse et al., 2008; Colombrita et al., 2009; Volkening et al., 2009; Freibaum et al., 2010) , we now discuss these findings in our revised manuscript and speculate on why TDP-43 is absent from stress granules/ FUS inclusions in our experiments (also see point 3 of reviewer 2).
(3) Finally, considering the strong labeling for PABP-1 in FUS-pathology and in the FUScontaining stress granules observed by the authors, have they tried to perform co-IP analyses to check for an eventual direct interaction between these two proteins?
While this manuscript was under review, we extended our analysis of stress granule markers and could show that in addition to PABP-1, several other well-established stress granule marker proteins (TIAR, TIA-1 and G3BP1) co-localize with FUS in cytoplasmic granules. We include this novel data in new Fig. 6A and new supplementary figure S4A . Furthermore, we now demonstrate that in addition to PABP-1, FUS inclusions in patients with FUS pathology contain the stress granule marker protein eIF4G (new Fig. 7B) . Collectively, these data show that multiple stress granule-associated proteins co-localize with FUS in stress granules. Thus, cytosolic FUS is recruited to bona fide stress granules. The fact that such stress granules are also formed in the absence of cytosolic FUS suggests that FUS is not an essential component required for assembly and stability of stress granules. Since FUS-positive stress granules contain at least four (if not more) different stress granule-associated proteins, co-IP would be expected for all of these proteins, but would not prove a direct interaction of FUS with one specific stress granule marker protein.
Reviewer 2:
Minor points:
(
1) The mutations that the authors focused on to determine their subcellular localization. It is rather surprising that they overlooked the two most frequent mutations, which have been identified by a number of groups, R521C and R521H. The authors did however analyze the pattern of expression in post-mortem tissue of an ALS patient with the R521C.
The reviewer is correct that that the most frequently identified mutations are R521C and R521H. We therefore followed the reviewer´s suggestion and analyzed the effect of the R521C and R521H mutation on subcellular localization of FUS. Both mutations had a very similar effect as the R521G mutation and led to a mild cytosolic mislocalization of FUS. We include this novel data, including quantification, in the new supplementary figures S1A & B of the revised manuscript.
(2) The authors should be cautious not to overinterpret their results in the discussion section since very few cases with FUS mutations have been identified up to now to discuss the severity of disease in these ALS patients.
Following the reviewer´s advice, we modified the discussion section and now discuss the correlation between the mutations' cytoplasmic mislocalization and the age of disease onset more carefully. We state that only a limited number of cases have been identified to date and for each mutation include the number (n) of patients identified so far. Indeed, it is correct that several reports have described TDP-43 in stress granules (Moisse et al., 2008; Colombrita et al., 2009; Volkening et al., 2009; Freibaum et al., 2010) . We now discuss these findings in our revised manuscript and speculate why TDP-43 is absent from stress granules/ FUS inclusions in our experiments. Briefly, we suggest that according to our two hit model, cytosolic relocalization might be a prerequisite for stress granule recruitment of TDP-43. TDP-43 was predominantly nuclear under our experimental conditions, whereas it might have been partially mislocalized to the cytosol in the studies cited above. Nevertheless, we would like to point out that we have carefully demonstrated the absence of TDP-43 in FUS-containing stress granules (new Fig.  5D , new Fig. 8C ) and in FUS inclusions in fALS and FTLD-FUS patients (Fig. 7) (also see point 2 of reviewer 1). Figure 5 .
We thank the reviewer for this excellent suggestion and followed his/her advice to treat cells with cycloheximide during heat shock or after GFP-M9M expression. Indeed in both settings, cycloheximide completely suppressed the formation of stress granules and also prevented the formation of FUS-positive granules. We include this functional verification in a set of new figures (Fig. 6B and supplementary figure S4B ) in the revised manuscript.
Furthermore, we extended our analysis of stress granule markers and now show that in addition to PABP-1 and TIAR, two other well-established stress granule marker proteins (TIA-1 and G3BP1), but not the P body marker Dcp1, co-localize with FUS in cytoplasmic granules (new Fig.  6A and new supplementary figure S4A ). These experiments further underscore that the FUS+/TIAR+/PABP-1-positive granules are indeed stress granules.
(2) The demonstration that PABP-1+ granules are found in tissue sections from patients with ALS and FTLD-U is suggestive of stress granules, but additional evidence would be welcome. Is it possible to subject these tissues to in situ hybridization using oligo-dT to determine whether poly(A)+ RNA is present at these granules?
We agree with the reviewer that the detection of additional stress granule components in inclusions of ALS and FTLD-U patient would strengthen the hypothesis that these inclusions might be derived from stress granules. Due to post-mortem delay, which significantly affects RNA
